TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04391062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: patient will receive 5-ALA 4 to 6 hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: patient will receive 5-ALA 4 to 6 hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: patient will receive 5-ALA 4 to 6 hours before surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative PDT
Description: The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative PDT
Description: The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative PDT
Description: The protocol requires the realization of specific procedures in addition to the usual care.~The intra-operative photodynamic therapy (intraoperative PDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with different J/cm²) at the end of resection (Prolonged surgery of 45 minutes).
Study: NCT04720638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short fiber reinforced flowable resin composite restorations
Description: reinforced flowable resin composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resin composite restoration
Description: Microhybrid resin composite
Study: NCT05495997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery Training
Description: Participants will practice mental imagery of everyday tasks daily for 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants will receive psychoeducation on cognition and brain health.
Study: NCT05062434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing and audit and feedback intervention
Description: An academic detailing and audit and feedback intervention will be presented to VA cardiac electrophysiologists, and will include quantitative data about the individual physician's facilities cardiovascular implantable electronic device lead implants and national data on lead implants over the past year.
Study: NCT05896280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EST
Description: Stones are taken by cutting the papillary sphincter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EST
Description: Stones are taken by cutting the papillary sphincter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECPP
Description: During ERCP, a generous biliary sphincterotomy (\>1 cm) will be performed to facilitate large stone extraction by use of a lithotripsy basket and a stone extraction balloon. After all stone fragments were cleared from the bile duct, this group will undergo ECPP after EST. A single-pigtail biliary stent will be placed (suspended overlength biliary stent, 7F × 20 cm). Then the rotatable repeatable opening and closing of soft tissue clamps (referred to as harmony clips, Mico-Tech, ROCC-D-26-195) should be applied to extend the bile duct axially, linear clamp the incised duodenal papilla, taking care to avoid clamping the bile duct stent, and removing the bile duct stent 3 weeks after ECPP.
Study: NCT05662618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous selective arteriography of peripheral arteries
Description: Paclitaxel coated balloon catheter for the treatment of stenosis or occlusion of superficial femoral artery and/or popliteal artery.
Study: NCT05662514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BLa80
Description: Test product contain 3 × 109 colony-forming units \[CFU\] Bifidobacterium animalis subsp. lactis BLa80 strains, for each packet.~Subjects ingested one packet (3 g/packet) of Test product per day (2 hours after taking antibiotics in the evening), for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To maintain the blinding, patients in the control group received placebo included in identical packets. Control product per day (2 hours after taking antibiotics), for 14 days.
Study: NCT06411093

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Kinesiology tape wrapping
Description: Place Kinesiology tape between the nail plate and the inflamed periungual granulation tissue in addition to conventional treatment for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment including silver nitrate cauterization
Description: Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment including silver nitrate cauterization
Description: Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
Study: NCT05723432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6001
Description: KD6001 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered intravenously.
Study: NCT05275985

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI Positron Emission Tomography-Computed Tomography
Description: The patients with suspected pancreatic lesions were included. They underwent 68Ga-FAPI PET/CT to distinguish benign and malignant lesions, to evaluate the resectability of lesions and to detect distant metastasis. The treatment methods were decided according to the results of 68Ga-FAPI PET/CT.
Study: NCT05800652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring Program
Description: Mentoring program created in academic, social, emotional and safety dimensions.In the academic dimension, there is information about the instructors, course selection, preparing a course study program,efficient study methods,information about the education and training program. Social dimension includes interpersonal relations, participation in social life, free time activities, making friends.The emotional dimension includes developing self-confidence,coping with stress,belonging and motivation.In the security dimension, there are student rights,scholarship opportunities, accommodation opportunities, library and internet facilities, use of the health center and clinical practice. In the mentoring program, it was expected that the mentors would make individual meeting(s) with the mentee they were matched with, face to face, online or over the phone, and share information and support every week. The mentoring program continued for 12 weeks.
Study: NCT04772807

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone

Intervention type: DEVICE
Intervention: Kinocardiograph
Description: Measure with the Kinocardiograph device and the Okcardio application installed on a smartphone
Study: NCT05229445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitor based insulin bolus calculator
Description: Participants will use the bolus calculator with meals to calculate their insulin bolus doses
Study: NCT05304481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATL administration
Description: Subjects have ATL administration using intravenous infusion
Study: NCT05407987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Ferric Derisomaltose is a solution based iron supplement provided in 100 mg elemental iron/mL. Patients randomized to Iron Therapy Arm will with a bodyweight \<50kg will receive 500mg of Ferric Derisomaltose, and patients with a bodyweight \>50kg will receive 1000mg of Ferric Derisomaltose, to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg. Patients will receive a single infusion between 21 and 90 days preceding surgical intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the Placebo arm will receive 100mg of normal saline over 1 hour.
Study: NCT05850845

Intervention type: DEVICE
Intervention: Microscopic hyperspectral imaging system
Description: CTX for idiopathic membranous nephropathy

Intervention type: DEVICE
Intervention: Microscopic hyperspectral imaging system
Description: CTX for idiopathic membranous nephropathy
Study: NCT04813705

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose
Description: The patients with CMR and more than 70% PMR at 25th fraction will receive reduced-dose radiotherapy for 30 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional dose
Description: The patients who do not achieve CMR or 70% PMR at 25th fraction will receive conventional dose radiotherapy for 33 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
Study: NCT05450614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrive app
Description: The application has already been developed using the Flutter framework and provides users with the main CBT-based strategies to reduce depressive symptoms. In order to engage users, gamification strategies were also implemented. Some examples are 1) development and achievement: quiz on psychoeducation with rewards; 2) epic sense: like the messages in the psychoeducation session; 3) unpredictability: surprise quiz. An avatar will also be available for the participant, who will gain experience as he interacts with some of the application's functions. Finally, participants will receive weekly videos of less than 5 minutes with tips on how to use the app. There will be a total of 12 videos with psychoeducation tips and how to use the application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCCG
Description: In the literature, there is no single protocol for the treatment of depression through CBCT, therefore, a systematized protocol was developed for this study, aiming to structure and unify this intervention. Participants selected for the TCCG group will be randomly divided into 10 groups of 10 members each. The TCCG will be held through weekly meetings, exclusively online. Twelve sessions lasting 90 minutes each will be applied. The structuring of the sessions is based on the cognitive-behavioral model, starting with psychoeducation about the disorder and self-knowledge, starting with cognitive restructuring and relapse prevention. Homework will be part of the protocol. The sessions will be held on a digital platform (Google Meet) and access instructions will be provided to the participants of this group in the evaluation interview.
Study: NCT04764214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3rd generation EGFR-TKI
Description: Osimertinib will be administered orally at the dose of 80 mg once daily.
Study: NCT05277948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active thumbtack needle
Description: The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham thumbtack needle
Description: The following 12 acupoints including conception vessel (CV) 4, CV3, bilateral ovary acupoints, bilateral spleen (SP) 6, bilateral stomach (ST) 36, bilateral bladder (BL) 23 and bilateral EX-B7 will be used. Eight points of CV4, CV3, SP6, ST36 and BL23 were treated by the sterile sham thumbtack needle for single use (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM2-6YDL), and four points of bilateral ovary acupoints and bilateral EX-B7 were treated by disposable sterile sham electro-thumbtack needle (Hangzhou Zhuomai Medical Technology Co., LTD., model: ZM3-ZY).~The patients were receive a treatment of 2 menstrual cycles
Study: NCT04764214

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidative SRT
Description: Patients who possess oligoresidual disease after 3rd generation EGFR-TKI therapy will be treated with the intent to ablate all residual disease with consolidative SRT. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. TKI will be continued during and after consolidative SRT until disease progression or intolerable toxicity.
Study: NCT05571683

Intervention type: OTHER
Intervention: oxygen support
Description: 40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
Study: NCT05966337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Use of non-invasive ventilation in patients in group 2 with CPAP.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIPAP
Description: Use of non-invasive ventilation in patients in group 3 with BIPAP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care in phisicaltherapy
Description: Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care in phisicaltherapy
Description: Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual care in phisicaltherapy
Description: Patients undergoing usual physiotherapy treatment, consisting of a kinesiotherapy protocol
Study: NCT05571683

Intervention type: OTHER
Intervention: oxygen support
Description: 40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.

Intervention type: OTHER
Intervention: oxygen support
Description: 40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.

Intervention type: OTHER
Intervention: oxygen support
Description: 40 patients (2 arms) will be supported with 2 l/min oxygen and the other 2 arms (40 patients) will be supported with 4 l/min oxygen under the surgical drapes.
Study: NCT06419530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic formula capsule
Description: The subjects take 4 capsules a day for 84 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: The subjects take 4 capsules a day for 84 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMT capsule
Description: The subjects take 4 capsules a day for 84 days.
Study: NCT06411171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (FLOT)
Description: The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab plus chemotherapy (FLOT)
Description: The experimental group was treated with pembrolizumab combined with FLOT, and the control group was treated with FLOT chemotherapy alone
Study: NCT05324904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: - Vitamin D~* The aqueous solution of vitamin D3 (cholecalciferol) will be used ampoule 200,000 IU/2 ML,~* Using a 27-gauge syringe with the bevel facing upward, a maximum of 0.6 ml (60,000 IU) of vitamin D3 solution will be slowly injected into the base of the largest plantar wart (large warts \> 10 mm need multiple injections at different sites)~* Treatment sessions will be performed at 3-week intervals for a maximum of 4 sessions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: -Acyclovir~* Acyclovir vial (Zovirax® vial, 250mg, ) will be diluted with 3.5 ml saline to get approximately 70 mg /ml solution.~* After sterilization of the skin, a 27-gauge syringe with the bevel facing upward will be inserted into the base of the largest plantar wart to slowly inject the solution~* Treatment sessions will be performed at 2-week intervals for maximum of 5 sessions
Study: NCT06277453

Intervention type: OTHER
Intervention: surgery
Description: radical gastric cancer surgery (R0) and D2 lymph node dissection

Intervention type: OTHER
Intervention: surgery
Description: radical gastric cancer surgery (R0) and D2 lymph node dissection
Study: NCT06501846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pipelle® endometrial biopsy performed under transabdominal ultrasound guidance
Description: The placement of an ultrasound probe on the lower abdomen while a Pipelle® endometrial biopsy is obtained.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pipelle® endometrial biopsy performed without ultrasound guidance
Description: A Pipelle® endometrial biopsy is performed by using touch alone.
Study: NCT05306132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASKC202
Description: Dosage Forms: Tablets; Administration: Oral administration
Study: NCT05095142

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT05883098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound debridement
Description: The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound debridement
Description: The study's wounds will be mechanically debrided before the experimental or active comparator devices are applied. Debridation will be performed by a trained clinician using a curette. Necrotic tissue and slough will be removed during this procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wound closure matrix application
Description: After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound closure matrix application
Description: After wound debridement, the patients will receive the application of a wound closure matrix as dictated by their randomization allocation.
Study: NCT06427083

Intervention type: DRUG
Intervention: Envlo Tablet
Description: Enavogliflozin 0.3mg

Intervention type: DRUG
Intervention: Envolomet SR Tablet
Description: Enavogliflozin 0.3mg/Metformin1,000mg
Study: NCT05050591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Specific Silicone Airway Stent
Description: The Patient-Specific Airway Stent is a silicone stent indicated for use in adults that have stenosis of the airway. Current silicone stents have stock dimensions that do not conform to the patient's airway anatomy. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally design the stent to his/her desired dimensions. Finally, according to the physician's design, a patient-specific stent can be manufactured using additive manufacturing technology. The patient-specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.